Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Arterio-venous fistula for automated red blood cells exchange in patients with sickle cell disease: Complications and outcomes
source: American Journal of Hematology
year: 2017
authors: Delville M, Manceau S, Ait Abdallah N, Stolba J, Awad S, Damy T, Gellen B, Sabbah L, Debbache K, Audard V, Beaumont JL, Arnaud C, Chantalat-Auger C, Driss F, Lefrère F, Cavazzana M, Franco G, Galacteros F, Ribeil JA, Gellen-Dautremer J
summary/abstract:Erythrocytapheresis (ER) can improve outcome in patients with sickle cell disease (SCD). A good vascular access is required but frequently it can be difficult to obtain for sickle cell patients. Arterio-venous fistulas (AVFs) have been suggested for ER in SCD supported by limited evidence. We report the largest cohort of ER performed with AVFs from three French SCD reference centers. Data of SCD patients undergoing ER with AVFs in the French SCD reference center were retrospectively collected. The inclusion criteria were: SS or Sβ-Thalassemia and AVF surgery for ER. SCD-related complications, transfusion history, details about AVF surgical procedure, echocardiographic data before and after AVF, AVF-related surgical and hemodynamical complications were collected. Twenty-six patients (mean age 20.5 years, mean follow-up 68 months [11-279]) were included. Twenty-three patients (88.5%) required central vascular access before AVF. Fifteen AVFs (58%) were created on the forearm and 11 (42%) on the arm. Nineteen patients (73%) had stenotic, thrombotic or infectious AVF complications. A total of 0.36 stenosis per 1,000 AVF days, 0.37 thrombosis per 1,000 AVF days and 0.078 infections per 1.000 AVF days were observed. The mean AVF lifespan was 51 months [13-218]. One patient with severe pulmonary hypertension worsened after AVF creation and died. We report the first series of SCD patients with AVF for ER, demonstrating that AVFs could be considered as a potential vascular access for ER. Patients with increased risk for hemodynamic intolerance of AVFs must be carefully identified, so that alternative vascular accesses can be considered.
organization: Necker-Enfants-Malades-University Hospital, APHP, Université Paris 5; Henri Mondor University Hospital, APHP, Université Paris-Est Créteil; La Roseraie Clinic, Aubervilliers; Interventional Radiology Clinique Labrouste, Paris; Polyclinique de Poitiers; Centre hospitalier intercommunal de Créteil; Bicetre University Hospital, Université Paris 11; Clinique Arago, Paris; Poitiers University HospitalDOI: 10.1002/ajh.24600
read more full text
+myBinderRelated Content
-
First Sickle Cell Patient Dosed in Phase 2a of IMR-687This morning, Imara Inc. announced that ...
-
EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea...Background: Cerebral vasculopathy in s...
-
Kids with sickle cell disease aren’t receiving key vaccines, Michigan study findsA significant proportion of children w...
-
Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Si...BACKGROUND: Sickle cell disease (SCD) is...
-
Improving the Lives of People with Sickle Cell Diseasehttps://www.youtube.com/watch?v=NPaV0glX...
-
CTX001 Earns FDA’s Fast Track Status for Treating Sickle Cell DiseaseThe U.S. Food and Drug Administration (F...
-
Georgia Universities Join NIH-funded National Study of Bone Marrow Transplant for SCDThe Medical College of Georgia (MCG) and...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.